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Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is used
for the treatment of (paediatric) hypertension, heart failure and chronic
kidney diseases. Because its disposition, efficacy and safety differs across
the paediatric continuum, data from adults cannot be automatically
extrapolated to children. This review highlights paediatric enalapril
pharmacokinetic data and demonstrates that these are inadequate to
support with certainty an age-related effect on enalapril/enalaprilat
pharmacokinetics. In addition, our review shows that evidence to support
effective and safe prescribing of enalapril in children is limited, especially
in young children and heart failure patients; studies in these groups are
either absent or show conflicting results. We provide explanations for
observed differences between age groups and indications, and describe
areas for future research.
Introduction
Enalapril was the second angiotensin-converting enzyme (ACE) inhibitor to become
widely available for therapeutic use after captopril, the first registered oral ACE inhibitor.
Enalapril is an ethyl ester pro-drug, and its pharmacological effects are mediated by its
active metabolite, enalaprilat (also known as MK422). The main effect of enalaprilat is the
inhibition of ACE, a key component in the renin angiotensin aldosterone system (RAAS). This
leads to a decrease in the formation of angiotensin II and thereby to peripheral vasodilation.
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ing less sodium and fluid retention. These two mechanisms
cause a decrease in blood pressure (BP), and a decreased preload
and afterload of the heart [1]. In addition to its stimulatory
effect on aldosterone secretion, angiotensin II is able to directly
increase the activity of the epithelial sodium channel [2]. This
leads to maximum sodium reabsorption, a process that is also
reduced by ACE inhibitors. In adults, enalapril is used for the
treatment of hypertension and heart failure, as well as for
reducing proteinuria in chronic kidney disease (CKD). In addi-
tion to their BP lowering effect, ACE inhibitors have a role in the
treatment of patients with heart failure, because they prevent
(further) cardiac remodelling [3]. In CKD, the beneficial effect of
enalapril is mostly the result of a decrease in glomerular pressure
due to a relaxation of the efferent arterioles [4].
In children, enalapril is used for similar indications, but in the
European Union it is only authorised for use in children with a
body weight over 20 kg [5]. Although this label indicates a positive
benefit/risk ratio of enalapril on the basis of an evaluation by the
European Medicines Agency, data on the pharmacokinetics (PK)
and pharmacodynamics (PD) of enalapril in this population ap-
pear scarce. In children below the weight of 20 kg, even less data
are available. Current dose recommendations are based on empir-
ical evidence combined with data extrapolated from adult studies,
and as a consequence, a disparity in dosage criteria remains in
paediatric patients [6].
The importance of pharmacological treatment in children with
heart failure, especially dilated cardiomyopathies, is emphasised
by the low availability of donor hearts. Owing to this scarcity,
mortality within the first year of presentation remains extremely
high, highlighting the need for optimal treatment in children to
prevent or postpone transplantation [7].
This review aims to provide an overview of current knowledge
on enalapril PK and PD characteristics in children and identify
current knowledge gaps, as well as to suggest areas for furtherPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children
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FIGURE 1
Transport of enalapril through various membranes. Abbreviations: CES1, carboxyle
resistance-associated protein 4; OAT3, organic anion transporter 3; OATP1B1, organ
polypeptide 1B3.
2 www.drugdiscoverytoday.comstudy. Adult PK data are included if and when relevant to paediat-
ric PK data.
Pharmacokinetics
Disposition of enalapril
Because the active metabolite of enalapril, enalaprilat, is poorly
absorbed from the gastrointestinal tract, enalapril is administered
as a maleate salt to improve its absorption [8]. In adults, approxi-
mately 60–70% of enalapril is absorbed after oral administration
[8]. Data on the intestinal uptake mechanism show inconsistent
results. It has previously been hypothesised that enalapril is a
substrate for the low-affinity H+ peptide transporter 1 (PEPT1),
because its structure resembles Ala-Pro dipeptide or Xaa-Ala-Pro
tripeptide structures, which are intestinal PEPT1 substrates [9].
Because the reported affinity constants were significantly different
between studies, experiments were repeated [10,11]. Morrison
et al. studied the in vitro uptake of enalapril in both rat intestinal
rings and Caco-2 cells (human cells that resemble the enterocytes
lining the small intestine). Their results indicate that enalapril is
absorbed through a passive diffusion process and its transport is
non-saturable [10]. In three different cell experiments performed
by Knutter et al., an almost negligible affinity of enalapril for
transport by PEPT1 and PEPT2 was found [11]. Therefore, they
also concluded that transport in intestinal cells is not mediated via
those transporters. They postulate, based on the lipophilic char-
acteristics of enalapril, that uptake occurs via simple diffusion. On
the basis of these two studies, the involvement of a human
intestinal transporter in the uptake of enalapril is considered to
be unlikely. Whether this transport is paracellular or transcellular
remains to be undetermined.
In healthy volunteers, enalapril maximum serum concentra-
tions (Cmax) of around 45–49 ng/ml occur approximately 1 h after
oral ingestion of a 10 mg tablet [12,13]. However, these values are
measured using alkaline hydrolysis followed by ACE-inhibition
assays. This means that all enalapril and enalaprilat levels were: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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sterase 1; MRP2, multidrug resistance-associated protein 2; MRP4, multidrug
ic anion transporting polypeptide 1B1; OATP1B3, organic anion transporting
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prilat was directly measured but enalapril levels were deduced on
the basis of values obtained before and after hydrolysis. When
measured using a more recently developed high-performance
liquid chromatography method, enalapril Cmax values were
around ten times higher [14]. Also, a slight inaccuracy in deter-
mining enalaprilat concentrations using this method was demon-
strated when compared with newer assays, such as enzyme-linked
immunosorbent assays [15] or high-performance liquid
chromatography–tandem mass spectrometry [16]. In our review,
to compare adult and paediatric studies, we used the values derived
by the radioimmunoassay. The oral bioavailability of enalapril was
61% on the basis of urinary excretion data when intravenous
enalaprilat was used as a reference standard [17]. The elimination
half-life (T1/2) of enalapril is 1.6 (SD 1.5) h [14].
Conversion to enalaprilat
After absorption from the small intestine (Fig. 1), uptake of enalapril
in hepatocytes is mediated by the organic anion transporting poly-
peptide 1B1 (OATP1B1) and OATP1B3 [18]. Approximately 60% of
enalapril is metabolised in the hepatocyte to its active metabolite,
enalaprilat, by one of the major hepatic hydrolases, carboxylesterase
1 (CES1) [13]. By removing the ethylester from enalapril to form
enalaprilat, the molecule becomes negatively charged, and its po-
tencytoinhibitACE increases. Following its formation,enalaprilat is
transported into the systemic circulation by multidrug resistance-
associated protein 4 (MRP4) [19]. But, because hepatic MRP4 expres-
sion is highly variable [20], the involvement of other basolateral
transporters cannot be excluded. Although most enalapril will be
eventually excreted renally as enalaprilat, untransformed enalapril
is excreted in bile by MRP2 [18] or excreted back into the systemic
circulation by an unknown transporter.
Peak concentrations of enalaprilat are observed between 3.5 and
4.5 h after ingestion in healthy adult volunteers and are between
54.8 and 57.2 ng/mL [14] after a dose of 10 mg. These values
coincide with maximum inhibition of ACE [12], and over the
usual therapeutic range, there is a direct linear correlation between
the Cmax of enalaprilat and given dose of enalapril [21]. The
observed area under the curve (AUC0–infinity) was 255.9–266.9 ng
h/ml [14]. The protein binding of enalaprilat in the circulation is
reported to be a little less than 50%, and it penetrates into most
tissues, including the vascular endothelium of the lungs [21]. In
the lung, ACE exists at the endothelial cell surface, where it is shed
and hydrolyses circulating peptides [22].
Elimination
The excretion of enalaprilat is predominantly renal; 43% of the
enalapril dose is recovered in urine as enalaprilat and 18% is
recovered as enalapril [13]. This renal elimination of enalaprilat
is biphasic. The initial phase seems to reflect glomerular filtration
combined with tubular secretion, followed by a later phase that
reflects the equilibrium of the drug from tissue distribution sites
[23]. The entry of enalaprilat into the proximal tubular lumen is
thought to be transporter-mediated, because the clearance of
enalaprilat exceeds that of the glomerular filtration rate (GFR)
marker inulin. This suggests that the elimination is based on
glomerular filtration as well as on tubular secretion [24]. Because
enalaprilat is an anion and the excretion of another ACE inhibitorPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children(quinalaprilat) excretion is decreased in the presence of organic
anions [25], it is likely that this secretion is mediated by an organic
anion transporter. This was indeed confirmed by Ni et al., who
showed that the uptake of enalaprilat is mediated by the organic
anion transporter 3 [26].
Reported clearances of enalaprilat range from 158 (SD 46) ml/
min [13] to 173 (SD 13) ml/min [27], determined after adminis-
tration of enalapril. After oral administration of enalapril or intra-
venous administration of enalaprilat itself in healthy adult
volunteers, the effective half-life of enalaprilat after multiple doses
range from 3.5 to 11 h [12–14,27,28]. The terminal half-life is
much longer at 35–38 h, which is presumably caused by binding
of enalaprilat to ACE [28], thus leading to slower elimination. To
make steady-state predictions, the effective half-life should be
used; the prolonged terminal phase contributes little to the accu-
mulation of enalaprilat because this involves redistribution from
the tissue distribution sites.
Estimates of the volume of distribution (Vd) of enalaprilat are
not available in the literature but can be calculated using the
formula Vd = T1/2  clearance (CL)/0.693 [29], assuming 100%
conversion of enalapril to enalaprilat. This yields values between
47 and 148 l (CL derived from [13], T1/2 from [12–14,27,28].
Factors influencing PK
There are many factors that can influence enalapril PK, of which
disease is a major one. The PK of both enalapril and enalaprilat is
not altered in patients with hypertension [30]. In patients with
congestive heart failure (CHF), this is less apparent. Two PK studies
compared CHF patients to healthy volunteers and hypertensive
patients, respectively. A slower absorption rate was suggested in
CHF patients, but owing to the small sample size, no statistical
significance could be shown [31,32].
The absorption of enalapril tablets is not influenced by food
[33,34]. Interestingly, when studying the impact of food on an oral
enalapril suspension, a significantly longer enalaprilat Tmax, lower
Cmax and lower AUC 0–infinity for enalaprilat were seen in 48
healthy volunteers after intake of a high-fat meal compared with
fasting [35]. Because orally administered drug in tablet form is not
absorbed until the tablet disintegrates and the drug particles are
dissolved, it would be understandable if only the absorption of
tablets was influenced by food compared with enalapril solution,
not vice versa. But perhaps, when using an oral solution, more
enalapril can bind to food particles, leading to a lower percentage
available for absorption.
Hepatic impairment could theoretically alter the metabolism of
enalapril to enalaprilat and the transport of enalaprilat out of the
hepatocyte. The abundance of CES1 in cirrhotic livers is reduced to
25% in control livers [36]. A change in hepatic metabolism might
also occur in CKD due to the interference of uremic toxins with
transcriptional activation, causing inhibition of drug transporters
and drug-metabolizing enzymes [37]. in vitro data suggest that
disease status can also influence CES1 hydrolytic activity, because
interleukin-6 (IL-6) decreased the expression of CES1 and CES2 by
up to 60% [38]. Despite such a reduction, in vivo studies confirm-
ing the hypothetically lower enalaprilat levels are not available.
Because enalaprilat is renally excreted, renal impairment, de-
fined as a GFR below 30 ml/min/1.73 m2, will result in higher
enalaprilat serum concentrations. Indeed, this was shown by Kelly: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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88 ml/min/1.73 m2) [39]. Furthermore, in addition to higher
serum concentrations, reduced renal function led to longer times
to reach Cmax, because serum enalaprilat concentrations could
further increase when excretion was delayed. Tmax increased by up
to 24 h, and the highest Cmax observed was 214 ng/mL at a dose of
10 mg. This is four times higher than values observed in the
absence of renal failure [14]. Because there is no reason to assume
this will not be applicable to children, dose reduction of enalapril
in paediatric patients might be necessary to prevent the accumu-
lation of enalaprilat and further renal insufficiency. When taking
the above-mentioned disease factors influencing PK into account,
the effect of ACE inhibitor therapy still shows significant interin-
dividual variability. We now focus on the impact of age on
enalapril PK and PD variability.
Paediatric PK studies
We identified only three paediatric PK studies, including a total of
62 children with either hypertension [40] or HF [41,42]. This small
number of patients, and interstudy variability limits conclusions
on the PK of enalapril and enalaprilat in children and the potential
impact of age and other co-variates.
All enalapril and enalaprilat levels were measured using a
radioimmunoassay. Enalaprilat was directly measured, and enala-
pril levels were deduced on the basis of values obtained before and
after hydrolysis [27]. This radioimmunoassay method was the
same as in the referenced adult PK studies [12,13,27,28] and
was at the time deemed to be accurate for enalaprilat concentra-
tions over 2 ng/mL [43].
Enalapril PK
Two of the three studies described enalapril PK, in addition to
enalaprilat (Table 1). In the 2001 study by Wells et al., 40 hyper-
tensive children (aged 2 months to 15 years) received 0.07–
0.14 mg/kg enalapril once daily, administered as a dispersed sus-
pension [40]. The enalapril Tmax occurred approximately 1 h after
administration, compared with 0.5–1.5 h as reported for adults
[12,13]. Mean Cmax values ranged between 24.6 and 45.4 ng/mL
across the different age groups. Cmax values in adults receiving
average doses of 0.14 mg/kg were 45–49 ng/ml [12,13].
Nakamura et al. described the PK of enalapril after doses of 0.05
to 0.3 mg/kg in children with CHF (n = 12, age 10 days to 6.5 years)
[41]. As described above for adults, one needs to take into account
possible differences in PK in children with CHF versus other
children. The results are presented normalised to an enalapril dose
of 0.1 mg/kg. Enalapril T1/2 was 2.7 (SD 1.4) h in children older
than 20 days (n = 10, 11 observations), compared with 1.6 (SD 1.5)
h as reported for adults [14,27]. Furthermore, the AUC0–infinity in
children >20 days was 82.7 (SD 44.3) ng.h/mL, compared with
55.6 (SD 5.7) ng.h/mL in adults [27]. The T1/2 and AUC in two
neonates <20 days of age were 10.3 (SD 5.2) h and 268.7 (SD 138.9)
ng.h/mL, respectively, based on three observations.
Enalaprilat PK
In the Wells study, enalaprilat AUC0–24h and Cmax, normalised per
kg bodyweight, were significantly lower in nine children who were
between 2 and 24 months of age compared with 12 children aged
12–16 years [AUC0–24h 131.4 (95% CI 91.9–187.9) ng.h/mL versusPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children
4 www.drugdiscoverytoday.com272.7 (95% CI 197.3–377.0) ng.h/mL per 0.1 mg/kg, Cmax 13 (95%
CI 9.2–18.4) ng/mL versus 31.8 (95% CI 23.5–43.0 ng/ml] [40]. No
significant difference between the other age groups was observed.
When corrected for body surface area, the AUC and Cmax did not
differ between age groups.
The percentage of enalapril dose excreted in the urine was calcu-
lated on the basis of measured urinary recovery of enalaprilat. This
percentage might serve as surrogate marker of CES1 and hepatic
transporter activity because it largely reflects conversion of enalapril
to enalaprilat [40]. The mean percentage conversion of enalapril to
enalaprilat showed great variability. This was largest within the age
group of children from 1 to 24 months of age, with CI ranging from
42.6 to 89.1%. Across age groups, enalapril to enalaprilat conversion
proportions were 64.7 to 74.6% and did not differ significantly
between age groups. The observed difference in AUC between the
youngest and oldest age groups might suggest increased CES1 and
hepatic transporter activity in the youngest age group, but the
conversion data cannot confirm this hypothesis. Because the patient
numbers are small, an age-related change in either CES1 metabolism
or hepatic transport can therefore not be excluded.
Nakamura et al. observed a normalised enalaprilat AUC0–infinity
for children >20 days of 138.4 (SD 69.2) ng.h/mL per 0.1 mg/kg
enalapril [41]. Because all but two of Nakamura et al.’s subjects
were below the age of 24 months, this cohort might be comparable
in age to the youngest age group of Wells et al. [40].
In children with CHF aged >20 days to 24 months, the average
T1/2 of enalaprilat was 11.1 (SD 4.3) h, whereas Wells reported, in
the whole cohort, T1/2 of enalaprilat up to 16.3 h, with large
interindividual variability, as shown in Table 1 [40]. In healthy
adults, T1/2 ranges from 3.8 to 11 h, whereas in adults with CHF, a
mean (SD) T1/2 of 6.8 (SD 2.5) h was found [32].
The third PK article from 1989 describes a dose-finding study in
ten paediatric patients (aged 6 weeks to 8 months) with CHF [42]. A
dose escalation protocol was used, with dosages as low as 0.02 mg/
kg in some children. These low doses resulted in a high proportion
of the 24 h enalaprilat serum samples (four out of the ten children)
being below the lower limit of quantification. Consequently, no
useful PK parameters could be obtained from those children. In six
children receiving the highest dose of 0.08 mg/kg, the serum T1/2
of enalaprilat was 7.55 (SD 0.66) h and the Cmax was 12.7 (SD 2.9)
ng/mL per 0.1 mg/kg dose of enalapril.
Overall, the available PK data are too limited to support with
certainty an age-related effect on enalapril and enalaprilat PK.
Lower enalaprilat exposure after bodyweight-normalised dosing in
young infants, as suggested by the Wells study, could be supported
by the data from the two other PK studies, but all together, the
small patient numbers across a wide age range and the difference
in the underlying disease preclude definitive conclusions.
The unknown interplay of the different PK processes involved in
the disposition of both enalapril and its active metabolite further
hampers simple extrapolation of knowledge on the maturation of
these processes to support the suggested age-related variation.
CES1 protein abundance increases fivefold from neonates to adults
[44]. At birth, the GFR is low, and at around two years of age, the
GFR reaches its maximum value of around 3.2 ml/min/kg; hereaf-
ter, it decreases to reach adult values from the age of five onwards
[45]. Although data on the ontogeny of hepatic MRP4 in humans
are lacking, a juvenile rat study showed low expression at birth and: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
Drug Discovery Today Volume 00, Number 00 August 2020 REVIEWS
DRUDIS-2762; No of Pages 14
TABLE 1
PK of enalapril and enalaprilat in children compared with adults
Wells et al. 2001 [40] Nakamura et al. 1994 [41] Lloyd et al. 1989 [42]
Age range and number of patients 2 months–15 years: 40 <20 days: 2
20 days to 6.5 years: 10
21–39 years : 7
6 weeks–8 months: 10
Diagnosis Hypertension CHFa CHF
Dose 0.07–0.14 mg/kg Children: 0.05–0.3 mg/kg
Adults: 10 mg
0.02–0.08 mg/kg
Pharmacokinetic parameters of enalapril
Cmax, mean 24.6–45.4 ng/ml – –
Tmax, mean 1 h – –
AUC0–infinity in ng.h/mL, mean (SD) – <20 days: 268.7 (139.9) –
>20 days: 82.7 (44.3)
T1/2 in h, mean (SD) – <20 days: 10.3 (5.2) –
>20 days: 2.7 (1.4)
Pharmacokinetic parameters of enalaprilatb
AUC per 0.1 mg/kg (ng.h/mL)
Wells: AUC0–24h, geometric mean (95% CI)
Nakamura: AUC0-1, mean (SD)
2–24 months 131.4 (91.9–187.9) <20 days: 691.5 (225.6)
>20 days: 138.4 (69.2)
–
2–6 years 140.7 (98.4–201.3) –
6–12 years 176.3 (125.6-247.5) – –
12–16 years 272.7 (197.3–377.0) – –
Adults – 245.7 (61.8) –
Cmax per 0.1 mg/kg (ng/mL)
Wells: geometric mean (95% CI)
Nakamura: mean (SD)
Lloyd: mean (SD)
2–24 months 13 (9.2–18.4) <20 days: 5.3 (3.0)
>20 days: 9.0 (4.7)
12.7 (2.9)
2–6 years 18.4 (13–26.1) –
6–12 years 22.7 (16.3–31.7) – –
12–16 years 31.8 (23.5–43)
Adults – 30.3 (14.0) –
Tmax (h)
Wells: median (95% CI)
Nakamura: mean (SD)
2–24 months 6.0 (4.0–8.0) <20 days:?
>20 days: 7.3 (2.4)
4
2–6 years 5.0 (3.1–6.9) –
6–12 years 5.0 (4.0–6.0) – –
12–16 years 4.0 (3.0–5.0) – –
Adults – 3.7 (1.4) –
T1/2 (h)
Wells: mean (95% CI)
Nakamura: mean (SD)
Lloyd: mean (SD)
2–24 months – <20 days:?
>20 days: 11.1 (4.3)
7.55 (0.66)
2–6 years 15.37 (9.45–28.07) –
6–12 years 16.31 (10.98–20.44) –
12–16 years 14.61 (10.22–23.00) –
Adults – 5.3 (1.6) –
a Abbreviations: AUCinfinity, area under the curve; CHF, congestive heart failure; Cmax, maximum serum concentration; T1/2, elimination half-life; Tmax:, time to maximum concentration.
b Aggregated AUC and Cmax values of enalaprilat reported by Wells and Lloyd et al. were normalised to a dose of 0.1 mg/kg per age group in order to facilitate comparison between
studies. Used formulas: AUC, dose/CL; concentration, dose/CL and assuming linear kinetics for Tmax as well as T1/2.
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transporters involved in enalaprilat excretion are currently un-
known.
Pharmacodynamics
Adults
Enalaprilat inhibits ACE, which leads to reduced formation of
angiotensin II. Following an enalapril dose of 10 mg in healthy
individuals, ACE inhibition (reflected by the reduced generation of
angiotensin II) was almost complete between 4 and 10 h after
administration. Accordingly, plasma renin levels increased with
maximum levels after 4 h, and both angiotensin II and aldosterone
levels decreased and remained low up to 10 h after administration
[1]. The relationship between ACE activity and plasma enalaprilat
levels, as well as BP and plasma enalaprilat levels, was inversely
proportional, as was shown by de Leeuw et al. in hypertensive
patients [47].
During decompensated cardiac failure, the RAAS is activated
owing to a lower cardiac output, leading to a decrease in periph-
eral vascular resistance and a diminished volume of the extracel-
lular fluid, but returns to normal when heart failure stabilisesPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children[48]. As would be expected, the formation of angiotensin II is
decreased in patients using enalapril, leading to lower levels of
angiotensin II, less activation of ACE and lower aldosterone levels
[49].
Children
Data supporting the increased activity of the RAAS during infancy
and childhood in healthy children (up to 4 years of age) have been
previously published and are widely accepted [50]. Interestingly,
and in a similar pattern to adults, after once-daily administration
of 0.25 mg/kg enalapril, inhibition of ACE activity in eight infants
with CHF (aged 3 weeks to 6 months) was 75.5% (SD 12.2%) at 4 h
after intake compared with ten healthy children without ACE
inhibitor treatment [51].
Angiotensin II concentrations decreased from 115 (SD 67) pg/mL
to 60 (SD 30) pg/mL and plasma renin activity increased from 25 (SD
24) ng/mL/h to 45 (SD 37) ng/mL/h in 35 children with CHF (aged 1
month to 17 years) after an average of 17 days of treatment with
enalapril at an average daily dose of 0.24 mg/kg twice daily [52]. To
the best of our knowledge, no PD parameters have been measured
during enalapril treatment in children with hypertension.: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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TABLE 2 (Continued )
Indication
(number of trials)
Reference Number of
patients
Age of population Exact indication Dosage and type of formulation
(duration)
Type of trial Level of
evidencea
[142]
Effect
Kidney disease (13) Webb et al. 2012
[88]
268 (134 enalapril) 10.4 (SD 4.7) years Children with proteinuria Suspension or tablet, mean dose
0.26mg/kg (12 weeks)
Double-blind RCT 1b The LS percent mean reduction from baseline in the urinary protein–
creatinine ratio was 40.45%. The LS mean change from baseline in eGFR
was 7.0ml/min per 1.73 m2 (both after 3 years).
Webb et al. 2013
[87]
27 (12 enalapril) 1–17 years Alport disease Suspension or tablet, 0.07–0.72mg/kg/
day (12 weeks)
Double-blind RCT 1b The LS mean percent change from week 12 in urinary protein LS mean
change from week 12 in eGFR was 9.1ml/min/1.73 m2 in the enalapril
group
Caletti et al. 2011
[89]
46 (14 enalapril) 2.08–13.89 years Post-diarrhoea HUS 0.18–0.27mg/kg/day single oral dose (7
months)
Double-blind RCT 1b Decrease in proteinuria with enalapril was 66.3%. Significant decrease SBP
of 12% (p< 0.023) after treatment with enalapril (no change after placebo
or losartan).
Bagga et al. 2004
[90]
25 1–16 years Steroid-resistant nephrotic
syndrome
0.2–0.6mg/kg/day (2 8 weeks) Randomised crossover trial (open label) 1b High-dose enalapril (0.6mg/kg/day) was associated with a significant
reduction in urine albumin-to-creatinine ratio (p < 0.01)
Hari et al. 2013
[91]
41 (20 enalapril) 2–18 years CKD 0.4mg/kg/day tablet once daily (1 year) Open-label RCT 1b The rate of decline in GFR was 3.0 (SD 4.2) in the enalapril and 4.2 (SD 5.1)
ml/min/1.73m2 in the non-enalapril group (p=0.51)
Sasinka et al.
1999 [92]
48 (17 enalapril) Unknown Proteinuric children Unknown (8 weeks) Retrospective study 2b Proteinuria decreased from 1.32 (SD 0.23) to 0.53 (SD 0.11) and 0.44 (SD
0.07) g/day on the 4th and 8th week of treatment
Proesmans et al.
2000 [93]
7 5.15–13.75 years Alport syndrome Tablet, 0.13–0.29mg/kg/day (24
months)
Case study (prospective) 4 Marked reduction in urinary protein excretion with a nadir of 23% (52mg/
kg to 12mg/kg per 24 h) of the baseline at 18months; no p-value reported
Guez et al. 1998
[95]
1 22 months (born at 35
weeks gestation)
Finnish-type congenital
nephrotic syndrome
0.8mg/kg/day (1 month) Case study (prospective) 4 Serum protein concentration was maintained without the need for
albumin infusions (no p-value reported)
Proesmans et al.
1996 [94]
5 7–17 years Various renal diseases 0.5mg/kg per day (24 months) Case study (prospective) 4 Median decrease in proteinuria of 52% (no p-value reported)
Trachtman et al.
1988 [96]
8 (1 enalapril) 5–22 years Proteinuria unresponsive for
standard therapy
2.5mg/day (undefined) Case study (prospective) 4 BP declined to the normal range in all cases and achieved a mean value of
112/73mm Hg (p < 0.005)
Caletti et al. 2013
[97]
17 0.25–5.33 years Diarrheal HUS 0.20–0.56mg/kg/day (5.92 years) Case study (retrospective cohort) 4 Decrease in proteinuria with enalapril was 58% (p=0.023)
Fitzhugh et al.
2005 [98]
3 14–17 years Sickle cell nephropathy 5–7.5mg/day (3.0 1.3 years) Case study 4 Increase in serum albumin levels from 2.8 (SD 0.8) g/dl to 3.9 (SD 0.3) g/dl
(no p-value reported)
Lama et al. 2000
[99]
6 ? Steroid-resistant nephrotic
syndrome
0.3mg/kg/day (2 years) Case study 4 In 71.4% enalapril therapy resulted in an important reduction of
proteinuria
a Level of evidence according to Johansen et al.: systematic reviews and meta-analyses of RCTs (1a), RCT (1b), non-randomised controlled trials (2a), cohort studies (2b), case-control studies (3), case studies, expert opinion.
b Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; BP, blood pressure; CHF, congestive heart failure; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration
rate; HUS, haemolytic uraemic syndrome; IV, intravenous; LS, least squares; LV, left ventricle; MAP, mean arterial pressure; RCT, randomised controlled trial; SBP, systolic blood pressure; SEM, standard error of the mean.
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In the paediatric population, enalapril is prescribed for patients
with hypertension, CHF and CKD (Table 2). We identified 36
articles reporting the clinical effect of enalapril in children with
(one of) these three different diagnoses. There was large heteroge-
neity both in the study methods and the outcome measures;
therefore, the results are described below by underlying disease
as well as level of evidence.
Hypertension
Children
Nine articles described the effect of enalapril in hypertensive
patients, and one meta-analysis studied the pharmacological treat-
ment of arterial hypertension in children and adolescents [53].
Together with lisinopril, enalapril seems to be superior in reducing
systolic BP (SBP) and diastolic BP (DBP) compared with other anti-
hypertensive agents. However, it is important to mention that the
conclusion of this meta-analysis is solely based on one dose–
response study investigating enalapril in 110 hypertensive chil-
dren aged 6–16 years [54]. Enalapril was administered as a suspen-
sion, and patients were randomised to receive a low, middle or
high dose. For children below 50 kg, this was 0.625, 2.5 or 10 mg of
enalapril once daily, respectively. Above 50 kg, 1.25, 5 or 20 mg of
enalapril was administered. A mean dose of 0.08 mg/kg seemed to
be effective at lowering BP within 2 weeks in most patients. Higher
doses were associated with a greater reduction in BP.
The other seven paediatric enalapril studies were excluded in this
meta-analysis because they did not compare enalapril to placebo.
One randomised controlled trial (RCT) compared the effectiveness
of valsartan, an angiotensin II receptor blocking agent, to enalapril
in 300 hypertensive children aged 6–17 years after a placebo run-in
period[55].Dosingwasbased onbodyweight,withdosesupto40 mg
of enalapril and 320 mg of valsartan. The study found a reduction of
14.1(SD8.5)mmHginmeanBPfrombaseline intheenalaprilgroup.
A similar reduction from baseline was seen in the valsartan group
(p < 0.0001). In 51 children aged 6 to 20 years of age after aortic
coarctation repair and hypertension, the superiority of enalapril to
atenolol, a beta blocker, was shown. This was based on the reduction
of the left ventricular mass index as well as 24 h SBP [56]. The
remaining five studies were all case studies or series with one to
15 patients, and suggested a similar trend with a reported (statisti-
cally) significant decrease in BP after various lengths of treatment
[57–61].
To further explore the dose–response relationship of enalapril, a
PK/PD model was developed to predict its efficacy in children aged
0–6 years using BP as the PD end point [62]. A two-compartment
model incorporating weight was built to predict a decrease in DBP
using three datasets, two of which were from children [40,54]. On
the basis of model predictions, researchers suggest that the dose–
response of enalapril is similar in children between 1 month and 6
years of age compared with those older than 6 years of age when
looking at the reduction of DBP after 2 weeks of treatment.
However, these data need further validation because no PD data
of children below the age of 6 years were used.
Next to age-related changes in PD, the effect of gender or sexual
maturity (Tanner stage) was also investigated and did not explain
variability in the antihypertensive effect of enalapril in 110 paedi-
atric hypertensive patients, aged 6–16 years [54].Please cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children
8 www.drugdiscoverytoday.comIn African American adults, it is well established that ACE
inhibitors are less effective in lowering BP, which is probably
explained by lower renin levels in this population [63]. In a
meta-analysis of six paediatric antihypertensive trials, BP de-
creased significantly from baseline in Caucasian (SBP p = 0.003,
DBP p < 0.0010), but not in African American children (SBP p =
0.139, DBP p = 0.397) [64]. However, although it is not mentioned
specifically for the paediatric population, the efficacy of ACE
inhibitors is promising even in cases of enhanced renin secretion
(hyper-reninaemic hypertension) [65,66].
In conclusion, moderate strong evidence supports the efficacy
of enalapril in treating hypertension in Caucasian children older
than 6 years of age. For younger children, data are scarce; for non-
Caucasian children, the efficacy may be lower.
Heart failure
Adults
Enalapril has a positive effect on heart-failure parameters beyond
its BP-lowering effect [67]. Because chronic volume overload will
lead to ventricular dilatation and myocardial hypertrophy in
certain forms of heart failure, irreversible structural and functional
damage will occur. By reducing cardiac afterload, ACE inhibitors
have been shown to reduce the extent of dilatation and develop-
ment of redundant cardiac muscle mass, thereby reducing left
ventricle (LV) volume overload and improving LV function [3]. As
well as a reduction in afterload, this effect can be explained by the
inhibition of hydrolysis of N-acetyl-seryl-aspartyl-lysyl-proline
(Ac-SDKP), which is an important inhibitor of stem cell prolifera-
tion. By raising Ac-SDKP concentrations, ACE inhibition leads to
reduced cardiac cell proliferation, inflammatory cell infiltration
and collagen deposition [68]. This also explains why enalapril is
beneficial in several types of heart failure.
Although the positive effect of ACE inhibitor therapy in adults
with heart failure is well established and ACE inhibitor therapy has
a major place in the therapy of adult heart failure in both Europe
and the United States [69,70], this effect is less apparent in the
paediatric population, in which studies show conflicting results.
Children
Fourteen studies addressed the efficacy of enalapril in children
with heart failure; two of these studies were double-blind placebo-
controlled randomised trials. These two RCTs comparing enalapril
to placebo were conducted in paediatric heart failure patients with
single ventricle physiology [71]. These children have a special
haemodynamic situation, and the clinical effects of enalapril
might not be comparable to other forms of heart failure. These
studies are therefore discussed at the end of this section.
Six prospective cohort studies investigated the effect of enala-
pril, and they all showed a significant effect on several heart failure
parameters (Table 2). In 24 patients aged 0.3–16 years with aortic
or mitral regurgitation, treatment with enalapril (or another ACE
inhibitor) led to a decrease in both posterior wall thickness and LV
mass [67]. Similarly, among children [mean age 4 years (SD 5.4
months)] with CHF, 39 out of 67 treatment periods in 63 patients
showed an improvement in clinical parameters after treatment
with enalapril [72]. Although no clinical end points were assessed
in 26 children aged 6 months to 15 years with a large ventricular
septal defect in the study of Webster et al., they found that after: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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by 20% [73].
In eight children with an isolated large ventricular septal defect
(aged <10 months), treatment with enalapril resulted in improved
bottle feeding and increased body weight [74]. In 35 children (aged
1 month to 17 years) with mitral or aortic regurgitation following
intracardiac repair or with dilated cardiomyopathy who received
enalapril, hepatomegaly significantly decreased as well as cardio-
thoracic ratio, heart rate and BP. LV end-diastolic dimension also
decreased [52]. Furthermore, in 11 children (aged 1–13 months)
with CHF secondary to a left-to-right shunt, systemic vascular
resistance was significantly decreased (18.1 (SD 4.7) to 14.2
(SD3.5) Wood units*m2, p < 0.001) after treatment with enalapril.
However, the reduction in pulmonary/systemic blood flow ratio
was not significant [75].
Ina retrospective study in81 children (mean age 3.6 (SD 0.6) years)
with a dilated cardiomyopathy, 27 children were treated with ACE
inhibitor alone (enalapril n = 2, or captopril n = 25) versus conven-
tionally with digoxin and diuretics (n = 54). Both captopril and
enalapril treatment showed a statistically significant better survival
rate during the first year compared to the other group (p < 0.05) [76].
Last, in three out of four reported case series, enalapril therapy
showed positive outcomes. The results of these studies can be
found in Table 2 [77–80].
The largest RCT on enalapril was performed in children with
single ventricle physiology [71]. Enalapril at an oral dose of 0.4 mg/
kg/day given in two divided doses did not improve somatic
growth, ventricular function or heart failure severity in 230 infants
(mean age 20 days) with a single ventricle that had stable systemic
and pulmonary blood flow [71]. Based on the hypothesis that
increased systemic vascular resistance and impaired diastolic func-
tion might contribute to decreased exercise capacity, a double-
blind crossover trial was performed in 18 post-Fontan procedure
patients (age 14.5 (SD 6.2) years, dose of 0.2–0.3 mg/kg/day for 10
weeks). Again, enalapril did not improve exercise capacity, sys-
temic vascular resistance, resting cardiac index or diastolic func-
tion [81]. However, it is important to note that patients with CHF
were excluded from this study.
As described above, the only two RCTs performed in children
with heart failure in post-Fontan procedure patients or patients
with single ventricle physiology failed to show an effect of enala-
pril on echocardiographic indices or clinical outcome. Yet these
findings need to be interpreted with great caution. In patients with
single ventricle physiology, the indication for ACE-inhibitor ther-
apy is not clear because this is a circulation with a potentially
underloaded systemic ventricle, especially after Fontan comple-
tion. But despite the absence of evidence, ACE inhibitors are still
used in a large proportion of these patients, partly due to potential
limitations of these studies [82]. In the Hsu et al. study, most
patients (80%) had preserved ventricular function in the absence
of neurohormonal activation at baseline, and systolic heart failure
is only a late manifestation and thus unusual in this population
[83,84]. In addition, there was a high rate of drug discontinuation,
and target doses were not achieved in all patients. Furthermore, as
the paediatric PK studies suggest, dosages of 0.07–0.3 mg/kg/day in
children less than 2 years of age might not reach a similar level of
enalaprilat exposure as in adults [40–42]. In the Hsu et al. study, the
enalapril target dose was 0.4 mg/kg/day. Also, in the Kouatli et al.Please cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in childrenstudy, enalapril was dosed at 0.2–0.3 mg/kg/day in children with a
single ventricle physiology [81].
Studies that showed a therapeutic effect of enalapril often also
included patients above the age of 12 years [52,56,67,73,77,78]
and/or directly administered enalaprilat [73–75]. Hence, in order
to investigate the effect of enalapril in children with heart failure,
new studies with higher dosages may be needed. Until then, low to
moderate level of evidence supports the efficacy of enalapril for
paediatric heart failure. For children with a single ventricle physi-
ology specifically, the data are less supportive.
Chronic kidney disease
Although it was initially developed as an antihypertensive drug,
enalapril is prescribed in patients with CKD with the aim of
reducing proteinuria and thereby improving renal survival [85].
Its positive effect on kidney survival can be explained by two
important factors [4]. ACE inhibitors in general decrease the
pressure within the efferent arteriole and thereby the intraglomer-
ular pressure. Furthermore, inhibition of cytokine production
results in less glomerulosclerosis and less fibrosis. However, it is
important to consider the differences in aetiologies of CKD, be-
cause the causes vary significantly between adults and children; in
the latter, a non-glomerular origin of CKD is more common.
Children
ACE inhibitors are used in 80% of children with CKD of glomerular
origin and only in 47% of those with non-glomerular CKD [86]. In
total, 13 studies described the use of enalapril in children with
various kidney diseases. Three double-blind RCTs were performed
in 341 children in total, aged 1–17 years, and they all reported a
significant decrease in proteinuria [87–89]. In two other open-label
trials in 66 children with Alport disease or post-diarrhoea haemo-
lytic uraemic syndrome (HUS) aged 1–18 years, enalapril signifi-
cantly decreased proteinuria [90,91]. Furthermore, one
retrospective cohort [92] as well as four prospective case studies
[93–96] in patients aged 22 months to 22 years showed a similar
result and supported the use of enalapril in this population. Last,
three retrospective case studies also investigated the effect of
enalapril, and all reported a positive effect on proteinuria in
children aged 0.25–17 years [97–99].
Taken together, these studies provide a moderate level evidence
to support the use of enalapril to reduce proteinuria in children
with CKD. Whether enalapril is also beneficial for clinical end
points such as dialysis-free survival or mortality remains un-
known.
Adverse events
In adults, the most common adverse reactions seen with the use of
enalapril are hypotension, renal failure, hyperkalaemia, cough and
angioedema [100]. Whether ACE inhibitor-associated kidney fail-
ure is caused by direct nephrotoxicity, renal efferent arteriolar
vasodilatation or hypotension and low renal perfusion remains
unclear [101]. Cough is considered to be a frequent side effect of
ACE inhibitor use, because it occurred in 13.5% of all patients on
ACE inhibitor therapy, but only 37% of these cases can be attrib-
uted solely to the use of ACE inhibitors [102]. Also, patients
suffering from allergic reactions to one ACE inhibitor have a
relative contraindication to another ACE inhibitor as well as to: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
www.drugdiscoverytoday.com 9
REVIEWS Drug Discovery Today Volume 00, Number 00 August 2020
DRUDIS-2762; No of Pages 14
Review
s
K
EY
N
O
TE
R
EV
IEWangiotensin II receptor blockers. However, for angioedema, a low
incidence of cross-reactivity is reported (<10%) [103].
In children, hypotension, impaired renal function and hyper-
kalaemia are the most commonly reported side effects of ACE
inhibitors [104]. In a systematic review of 11 reports covering a
total of 1050 paediatric heart failure patients taking enalapril,
hypotension was reported in 0–19% of cases, renal failure in 0–
29% and hyperkalaemia in 0–13% [104]. Articles that only includ-
ed patients treated with captopril were excluded. Reported differ-
ences across studies can be (partly) explained by differences in
adverse event definitions. There was no relation to dose, and
neither angioedema nor cough was reported.
Furthermore, the use of ACE inhibitors is not recommended
during the second or third trimester of pregnancy because of their
potential foetotoxicity [105]. This can be explained by suppression
of the foetal RAAS, which seems to disrupt foetal vascular perfu-
sion and GFR. Little data are available regarding the use of ACE
inhibitors during the first trimester. Animal data did not demon-
strate a teratogenic effect, and human case reports (n = 9) did not
record any embryo-foetal or postnatal outcome when enalapril
exposure was limited to the first trimester [105,106].
We identified four more articles describing adverse events in
children using enalapril. One case reported angioedema and hyper-
tension in a 14-year-old patient with systemic lupus erythematosus
whoreceived enalaprilatanunknowndosefor three years[107].One
paediatric cohort study of 42 patients (median age 7.6 years)
reported persistent isolated cough in 17% of patients using an
ACE inhibitor, of which the majority used enalapril [108]. Cough
resolved within days after discontinuing therapy. Furthermore, in
the study ofSeguchietal. (n = 35),acuterenal failure developed ina 3-
month-old infant one day after administration of enalapril, and
hyperkalaemia occurred in four children (12% of the study popula-
tion) [52]. All five adverse events resolved after discontinuation of
enalapril. Although adverse events were prospectively monitored in
the studyof Webster et al. [73], no adversereaction occurred inthe 26
children taking enalapril. Young children seem to be at an increased
risk of adverse reactions related to acute kidney injury (AKI) induced
by an ACE inhibitor because of their lower GFR and impaired
autoregulation of renal blood flow [104]. More specifically, children
of young age who are prone to dehydration, either owing to the
concomitant use of diuretics or gastro-enteritis, seem to be at a
higher risk of developing AKI-related adverse events.
In conclusion, enalapril seems to have a similar safety profile in
children compared to adults, but the incidence of cough and
angioedema seems to be much lower, although not completely
absent. To define the proportion of placebo-adjusted cases of
cough in children on ACE inhibitors, further studies are needed.
Drug–drug interactions
Adults
There are several compounds that can change efficacy and safety
when taking enalapril, and dose adjustments might be necessary
when taking enalapril together with other drugs. This includes the
concomitant use of enalapril with diuretics or other medications
working on the RAAS, such as angiotensin II receptor blockers or
renin inhibitors (aliskiren). One in three adult patients with
chronic heart failure developed AKI when ACE inhibitors were
co-administered with diuretics, compared with only 2.4% ofPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in children
10 www.drugdiscoverytoday.compatients who were on ACE inhibitor alone [109]. Due to a possible
decrease in GFR, caution is warranted when primarily renally
cleared medication that has a narrow therapeutic index (i.e.,
digoxin) or that increases the risk of AKI (non-steroidal anti-
inflammatory drugs) is co-administered. To decrease the risk of
developing hyperkalaemia, no potassium supplements should be
administered at the same time.
Children
Scant data are available about potential drug interactions and their
severity in children. An interaction described for adults is usually
also relevant for the paediatric population. However, the magni-
tude of these drug–drug interactions can differ greatly in children
when compared to adult data, because the extent of any drug–drug
interaction can be altered by physiological differences [110].
Onlytwo articles described enalapril interactions inchildren, albeit
in a very specific population. The therapeutic effect of allopurinol as
well as hydroxyurea increased when enalapril was co-administered
[98,111]. Emphasizing the importance of the possible development of
hyperkalaemia when taking enalapril with potassium supplements,
the interaction of enalapril with potassium chloride is within the top
five drug–drug interactions that were most frequently overridden in a
paediatric hospital [112]. For ACE inhibitor use in children, the co-
administration of furosemide is an independent risk factor for devel-
opingAKIinpatients [35,113].Thisriskfactorisalsosupportedbydata
from pharmacovigilance databases [101].
Drug formulation
In the published studies, children received extemporaneous liquid
formulations prepared from crushed tablets intended for adults.
Several problems can arise when using such extemporaneously
made medications. For example, inadequate mixing or settling of a
suspension increases the risk of medication errors [114]. Therefore,
several new formulations have been developed to ensure more
precise dosing in children. First, an enalapril oral solution has been
developed, thereby decreasing the risk of inappropriate prepara-
tion and reducing the risk of inadequate therapy in children
because a solution requires no preparation by nurses or parents.
Also, as an alternative, enalapril oral dispersible minitablets
(ODMTs) have been developed in the context of the EU Framework
Programme 7 labelling of enalapril from neonates up to adoles-
cents (LENA) project. Compared to an oral liquid, such solid oral
dosage forms have greater stability, easier transportation and
storage, and allow accurate dosing without the need for a volu-
metric measuring device [115].
The solution is bioequivalent to original tablet formulations
[35]. Enalapril ODMTs disperse in the mouth and have a slightly
higher Cmax but similar bioavailability to tablets [116]. These
newer formulations thus offer practical possibilities for more
accurate dosing in children [35,117]. In addition, ODMTs can
be successfully administered through paediatric nasogastric tubes
(Charrie`re 5) when dispersed in 1 ml tap water without causing
obstruction [115]. The PK and safety of these enalapril ODMTs are
currently being studied in children with heart failure [118].
When oral intake is undesirable, enalaprilat can be administered
intravenously. This makes enalaprilat the only intravenous ACE
inhibitor currently available, but availability of this intravenous
(IV) formulation is limited from the global perspective, only: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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Republic, Hungary and Ukraine. Moreover, its use is restricted
to acute situations [119].
Discussion
In this review we have summarised the available PK and PD paediatric
data. Although the efficacy of enalapril for the treatment of hyper-
tension and proteinuria in CKD seems to be supported by several
studies, the lack of a BP-lowering effect in African American children
raises the limitation of these efficacy data of across ethnicities. More-
over, the evidence for its use in children with heart failure remains
limited. It is important to realise that a positive effect of enalapril on
heart failure parameters in children with different kinds of heart
failure might exist, but the study designs used and the sample sizes
of study populations were not sufficient to demonstrate these ben-
efits. This problem was also addressed by Rossano et al., who described
differences between paediatric and adult heart failure populations
[120]. Moreover, the potential impact of age-related variation on
enalapril PK, as suggested by the limited PK data available, might
further contribute to variation in observed efficacy of enalapril be-
tween young infants and adults. Only limited PK data are available,
from 62 children in three studies, covering the paediatric age range
from neonate to adolescent. These studies suggest that enalaprilat
exposure might be lower in infants compared with older children and
adults, but the data across the paediatric age range (n = 60), including
neonates (n = 2), are too limited to draw any conclusions. If indeed
young infants need higher mg/kg doses to reach similar exposure to
adults, this might indicate that the lack of efficacy of enalapril
observed in some studies, including these younger age ranges, might
have been due to underdosing and not inefficacy of the drug.
Many years after approval of enalapril by the US Food and Drug
Administration, large unexplained inter- and intraindividual var-
iability in PK and PD exists, and the most prominent determinants
of this variability remain to be established. Additionally, although
some determinants of variations in enalapril PK were identified in
the adult population, including the effect of hypertension [30],
CHF [31,32], renal impairment [39], food [35] and race [63], these
factors do definitely not account for all interindividual variability
observed, let alone in the paediatric population.
Pharmacogenomics
Metabolomic and pharmacogenetic studies in children on ACE
inhibitors might be promising for further understanding the ob-
served variation. Pharmacogenomic analysis of patients on ACE
inhibitor therapy has led to the discovery of new leads for explain-
ing treatment responses. There are several genetic variants associ-
ated with ACE inhibitor effectiveness and safety, including
mutations in ACE [121]. Also, because CES1 enzymatic activity
has a key role in the conversion of enalapril to the active enala-
prilat, the role of CES1 gene variations was investigated. However,
in healthy adults, variations of the CES1 gene (the number of
functional gene copies) did not have a clinically relevant impact
on the metabolism of enalapril and could not explain the variabil-
ity in effect [122]. This finding is not in accordance with previous
published data, in which the AUC of another CES1 substrate
(methylphenidate) was markedly increased in individuals with
four copies compared with carriers of only two copies of the gene,
suggesting decreased metabolism [123]. The authors conclude thatPlease cite this article in press as: Smeets, N.J.L. et al. Pharmacology of enalapril in childrenobserved differences in the PK of enalapril must be explained by PK
differences other than CES1 genotype alone.
If, and to what extent, those genetic differences also contribute to
the variability in outcomes observed in children needs further study.
Pharmacogenomics in clinical paediatrics faces several challenges. For
example,expressionpatternsofgenesevolveduringdevelopmentand
will therefore be different over time, which makes extrapolating adult
data to paediatric clinical care challenging [124]. One study described
the association of RAAS-upregulation genotypes with failure of reverse
remodelling after superior cavopulmonary connection surgery, less
improvement in renal function and impaired somatic growth [125].
This offers the possibility of defining a high-risk group of single
ventricle patients who are at risk of therapy failure.
Metabolomics
Similar to pharmacogenetic profiling, metabolomics, the study of
small organic molecules within biochemical pathways, has proven
to be helpful to unravel part of the variability in observed disease and
response to therapy in adult patients. For example, in adults with
heart failure with preserved ejection fraction, a metabolomic ap-
proach has helped to reveal why the use of sildenafil was not
beneficial in this group of patients [126]. Also, in patients with
therapy-resistant hypertension, specific metabolite levels have been
shown to predict future response to spironolactone [127]. Numerous
metabolic alterations occur in the heart during adult heart failure,
involving several metabolic pathways [128]. Some of these metab-
olites showed significant associations with BP in patients using ACE
inhibitors and could therefore be of help in disentangling pathways
that affect the response to ACE inhibitors [129].
The therapy of (paediatric) heart failure is still mostly based on
targeting the downstream effects of heart failure instead of the
underlying cause. Heart failure in children is predominantly based
on genetic or inborn errors, contrary to adult heart failure, which is
often acquired [130]. A small number of metabolomic studies has
been conducted in the paediatric population, covering a variety of
underlying (non-cardiac) diagnoses. In these studies, different
metabolic profiles were identified in both healthy and diseased
children, thereby offering the opportunity to identify biomarkers
that have a diagnostic or therapeutic value [131–140].
To the best of our knowledge, no paediatric metabolomic studies
have yet been conducted in patients on ACE inhibitor therapy.
Unfortunately, adult findings cannot simply be extrapolated to
children for multiple reasons. First, human serum metabolic profiles
areage-dependent [141]. Second, paediatric heart failure differs from
adultheart failure inmany respects, including prevalence,aetiology,
clinical manifestation and comorbidities. Third, maturation of the
RAAS occurs in the first years of life, making the effect of ACE
inhibitor therapy more complex and the extrapolation of data more
prone to errors. Therefore, the metabolomic profile of children on
ACE inhibitor therapy warrants further study.
Concluding remarks
In conclusion, a major information gap remains on the PK and PD
of enalapril in children, especially in the youngest age groups, as
well as for the indication heart failure. To offer children evidence-
based enalapril therapy, further studies are needed to address these
information gaps, including PK and PD studies such as the EU-
funded LENA project [11,118].: a review, Drug Discov Today (2020), https://doi.org/10.1016/j.drudis.2020.08.005
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